4D Pharma Announces Opening of a Study Investigating MRx0518 in Combination with Radiotherapy in Patients with Resectable Pancreatic Cancer
4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces the opening of a clinical study to evaluate the safety and preliminary clinical efficacy of MRx0518 in combination with […]